M 106 (Zidovudine 300 mg)
Pill imprint M 106 has been identified as Zidovudine 300 mg.
Zidovudine is used in the treatment of hiv infection; reduction of perinatal transmission of hiv; occupational exposure; nonoccupational exposure and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). Risk cannot be ruled out during pregnancy. Zidovudine 300 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- M 106
- Strength:
- 300 mg
- Color:
- White
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- Nucleoside reverse transcriptase inhibitors (NRTIs)
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Mylan Pharmaceuticals Inc.
- National Drug Code (NDC):
- 00378-6106
- Inactive Ingredients:
- hypromelloses
magnesium stearate
microcrystalline cellulose
polyethylene glycol
sodium starch glycolate type A potato
titanium dioxide
More about zidovudine
Consumer resources
- Zidovudine
- Zidovudine capsules
- Zidovudine syrup
- Zidovudine injection
- Zidovudine (Advanced Reading)
- Zidovudine Intravenous (Advanced Reading)
- Other brands: Retrovir
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
